GW&K Investment Management LLC Boosts Stock Holdings in Bio-Rad Laboratories, Inc. $BIO

GW&K Investment Management LLC raised its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 24.9% during the third quarter, Holdings Channel reports. The firm owned 183,845 shares of the medical research company’s stock after purchasing an additional 36,632 shares during the period. GW&K Investment Management LLC’s holdings in Bio-Rad Laboratories were worth $51,550,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the stock. Dimensional Fund Advisors LP raised its position in shares of Bio-Rad Laboratories by 6.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,062,938 shares of the medical research company’s stock worth $298,019,000 after buying an additional 63,370 shares during the period. Teachers Retirement System of The State of Kentucky increased its stake in Bio-Rad Laboratories by 36.8% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 36,444 shares of the medical research company’s stock worth $10,219,000 after acquiring an additional 9,800 shares during the last quarter. Roubaix Capital LLC purchased a new position in shares of Bio-Rad Laboratories in the 3rd quarter worth about $2,275,000. Westfield Capital Management Co. LP raised its holdings in shares of Bio-Rad Laboratories by 11.5% in the 3rd quarter. Westfield Capital Management Co. LP now owns 155,524 shares of the medical research company’s stock worth $43,607,000 after purchasing an additional 16,019 shares during the period. Finally, TD Asset Management Inc lifted its stake in shares of Bio-Rad Laboratories by 461.0% in the 3rd quarter. TD Asset Management Inc now owns 8,988 shares of the medical research company’s stock valued at $2,520,000 after purchasing an additional 7,386 shares in the last quarter. 65.24% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

BIO has been the subject of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research report on Monday, December 29th. Wall Street Zen downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $358.50.

Bio-Rad Laboratories Price Performance

BIO stock opened at $284.83 on Thursday. The firm has a market cap of $7.69 billion, a P/E ratio of 10.21 and a beta of 1.18. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.19 and a current ratio of 5.62. Bio-Rad Laboratories, Inc. has a 1 year low of $211.43 and a 1 year high of $343.12. The stock has a 50-day simple moving average of $296.91 and a 200-day simple moving average of $301.34.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Thursday, February 12th. The medical research company reported $2.51 earnings per share for the quarter, missing analysts’ consensus estimates of $2.57 by ($0.06). Bio-Rad Laboratories had a return on equity of 3.86% and a net margin of 29.42%.The company had revenue of $693.20 million during the quarter, compared to analysts’ expectations of $694.64 million. During the same quarter in the prior year, the company earned $2.90 EPS. The firm’s revenue was up 3.9% compared to the same quarter last year. On average, equities analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Key Stories Impacting Bio-Rad Laboratories

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Zacks raised its Q1 2027 EPS forecast to $2.22 (from $2.12), a modest upward revision that could be read as a small near-term beat to expectations for that quarter.
• Neutral Sentiment: Zacks published an initial FY2028 EPS estimate of $9.87. As an early/forward-year projection this is informative but carries uncertainty and is not directly comparable to current-year consensus figures.
• Negative Sentiment: Zacks cut a string of near‑ and medium‑term EPS forecasts — small trims to Q1 2026 ($2.77), Q2 2026 ($2.34), Q4 2026 ($2.59) and FY2026 (to $10.32 from $10.36), and larger cuts to FY2027 (to $9.30 from $9.38) and several Q2–Q3 2027 quarters — signaling a weaker earnings trajectory than previously modeled. These downward revisions, taken together, are the main negative catalyst from this batch of research notes because they lower forward earnings expectations and could pressure valuation multiples.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.